Registration Details
The NC3Rs Technology Partn3Ring webinar series is an exciting new opportunity for SMEs and academics to showcase their technologies with 3Rs potential and connect with potential collaborators.
These webinars will consist of short pitches outlining 3Rs technologies that each have a unique opportunity for collaboration. Audience members will be able to ask questions to the speakers and learn about how to get involved in each collaboration.
The inaugural webinar will showcase:
- An in vitro platform to assess deep lung toxicity (ImmuOne)
- ConsoneIAI predicting toxicological outcomes for chemical structures (ConsoneAI)
-
In vivo Human As The Tox Species - Towards A Predictive In Silico Model Of Human Cardiovascular Tox For Early Drug Discovery (InoCardia)
- Next-generation LIVING-ORGAN systems to accelerate and de-risk preclinical research (PBLBio)
The webinar will be held over Zoom and is free to attend.
Speakers
Dr. Victoria Hutter, ImmuONE's Chief Scientific Officer: Dr. Victoria Hutter is a pharmacist by training with a strong research background. After completing her PhD in developing human cell models of the lungs, she spent 10 years as an academic at the University of Hertfordshire, securing over £7M in funding for innovative inhaled drug delivery and toxicology, drug transporters and in vitro toxicity assessment projects. In 2019, she co-founded ImmuONE, focusing on in vitro immunocompetent lung models. As a dynamic leader, Vicky oversees both scientific and commercial aspects of the company, collaborating with a dedicated team. Her research interests include inhaled therapeutics, drug transporters, and cellular toxicity assessment.
Mobeen Kosar, ConsoneAI: Mobeen has two degrees, first maths and then Biomedical science as a mature student. Mobeen has delivered projects with product development and international telecom product launches. As an entrepreneur, Mobeen has a passion and vision to reduce animal testing through her own personal experience, and for connecting data, skills and people to create and deliver innovative products and projects.
Dr Jeremy Nillson, InoCardia: Jeremy is CEO of InoCardia, a UK-based cardiovascular tox company specialising in drug-induced inotropy (heart pump power) assessment and in silico prediction of CV tox derived from human only data. Jeremy has a PhD in Medicinal Chemistry and over 30 year’s experience in pharmaceutical R&D, Business Development, senior level management and fund-raising within Pharma, Biotech, drug discovery service providers and academia. InoCardia’s technology has won multiple awards, it received the ‘One-To-Watch’ Award at the Medilink Midlands Business Awards 2023 and is a previous recipient of multi-year NC3R funding.
Prof James Fildes, Pebble Biotechnology: Prof Fildes worked in the NHS and academia for 25 years, leading research in transplant, trauma and critical care, and contributing to a wide range of clinical trials that changed NHS practices. In 2021 he founded Pebble, who offer advanced ex-vivo organ perfusion systems as a physiological test bed for drug development. The platform is therapy and disease agnostic, and is not recognised as animal research, as surplus biological material is used from the food industry. Pebble are also developing a pipeline of novel ex-vivo technologies for clinical use in transplantaton.